Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
                                          Medicine Chief, DeBakey VA Medical Center
                                          Houston, TX

Robert J. Mentz, MD
Chief, Heart Failure Section
Duke University Medical Center
Durham, NC

Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Harvard Medical School
Brigham and Women’s Hospital
Cardiovascular Medicine
Boston, MA

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Muthiah Vaduganathan, MD, MPH–disclosures to come.

Faculty:
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP–disclosures to come.
Robert J. Mentz, MD–has disclosed that he receives grants from American Regent, AstraZeneca, Boston Scientific, Cytokinetics, Medtronic, Merck, and Novartis. He receives research support from American Regent, AstraZeneca, Boston Scientific, Cytokinetics, Medtronic, Merck, and Novartis. He is an advisor or consultant to BI/Lilly, Bayer, Cytokinetics, Merck, Novartis, Pharmacosmos, Respicardia, Roche, Sanofi, and Vifor.
 

Peer Reviewer:
Information to come

CEC Staff/Planners:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.